Results 21 to 30 of about 24,552 (280)
Metszetek, 2022 Az elmúlt évtizedekben egyre nagyobb figyelmet kap a környezeti problémák és az ezzel ös - szefüggő társadalmi jelenségek vizsgálata. Az egyetemi hallgatók környezettudatosságának és környezettudatosságukat befolyásoló tényezőknek a megismerése ...
Ferenc Mónus +2 more
doaj +1 more source
Exploration of Targeted Anti-tumor Therapy, 2020 Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell receptor signaling and the irreversible BTK inhibitor ...
Rachael Arthur +3 more
doaj +1 more source
A Fast and Clean BTK Inhibitor [PDF]
Journal of Medicinal Chemistry, 2020 Bruton's tyrosine kinase (BTK) is a major drug target for B-cell related malignancies; however, existing BTK inhibitors approved for cancer treatment have significant off-targets that limit their use for autoimmune and inflammatory diseases. Remibrutinib (LOU064) is a novel covalent BTK inhibitor that binds an inactive BTK conformation, which affords ...
Ronen Gabizon, Nir London
openaire +2 more sources
Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
Journal of Innate Immunity, 2022 Humans with dysfunctional Bruton’s tyrosine kinase (Btk) are highly susceptible to bacterial infections. Compelling evidence indicates that Btk is essential for B cell-mediated immunity, whereas its role in myeloid cell-mediated immunity against ...
Zhe Liu +9 more
doaj +1 more source
Stimulation of the catalytic activity of the tyrosine kinase Btk by the adaptor protein Grb2
eLife, 2023 The Tec-family kinase Btk contains a lipid-binding Pleckstrin homology and Tec homology (PH-TH) module connected by a proline-rich linker to a ‘Src module’, an SH3-SH2-kinase unit also found in Src-family kinases and Abl. We showed previously that Btk is
Laura M Nocka +4 more
doaj +1 more source
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
PLoS ONE, 2023 Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj +2 more sources
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
Journal of Hematology & Oncology, 2021 B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu +4 more
doaj +1 more source
Kvantitatív drámaelemzés és az idő
Digitális Bölcsészet, 2023 A kvantitatív drámaelemzés legtöbbször a színművek egészére vonatkozó, statikus mérőszámokból indul ki, továbbá kevés figyelmet fordít az e mérőszámokkal leírt szerkezeti tulajdonságok történeti változásaira. A tanulmányban ezért korábbi eredményeinket,
Botond Szemes, Magyar Magyar
doaj +1 more source
Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader. [PDF]
LeukemiaSherpa MG +6 more
europepmc +2 more sources
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
Journal of Clinical Investigation, 2023 Bruton's tyrosine kinase (BTK) is a proven target in mantle cell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma. However, resistance to BTK inhibitors is a major clinical challenge. We here report that MALT1 is one of the top overexpressed genes in ibrutinib-resistant MCL cells, while expression of CARD11, which is upstream of MALT1, is ...
Vivian Changying Jiang +20 more
openaire +3 more sources